Trabectedin therapy for sarcomas

Current Opinion in Oncology

Volumn 22, Issue 4, 2010, Pages 342-346

  Casali, Paolo G ^a   Sanfilippo, Roberta ^a   D'Incalci, Maurizio ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

drug therapy; soft tissue sarcoma; trabectedin

Indexed keywords

DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; TRABECTEDIN;

ALOPECIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL DIFFERENTIATION; CHOLESTASIS; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL; DNA REPAIR; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; FATIGUE; HUMAN; HYPERTRANSAMINASEMIA; LIVER TOXICITY; MYXOSARCOMA; NAUSEA; NEUTROPENIA; NONHUMAN; PATIENT SELECTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPHYLAXIS; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; REVIEW; SINGLE DRUG DOSE; SOFT TISSUE SARCOMA; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; UTERUS MYOMA;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; DIOXOLES; DISEASE-FREE SURVIVAL; HUMANS; SARCOMA; SOFT TISSUE NEOPLASMS; TETRAHYDROISOQUINOLINES; TREATMENT OUTCOME;

EID: 77953911518     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32833aaac1     Document Type: Review

References (43)

1. Clark MA, Fisher C, Judson I, Thomas JM. Soft-tissue sarcomas in adults. N Engl J Med 2005; 353:701-711.
2. D'Incalci M, Jimeno J. Preclinical and clinical results with the natural marine product ET-743. Expert Opin Investig Drugs 2003; 12:1843-1853.
3. Erba E, Bergamaschi D, Bassano L, et al. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer 2001; 37:97-105.
4. Delaloge S, Yovine A, Taamma A, et al. Ecteinascidin-743: a marine derived compound in advanced, pretreated sarcoma patients-preliminary evidence of activity. J Clin Oncol 2001; 19:1248-1255.
5. Yovine A, Riofrio M, Blay JY, et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 2004; 22:890-899.
6. LeCesne A, Blay JY, Judson I, et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 2005; 23:576-584.
7. Garcia-Carbonero R, Supko JG, Manola J, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 2004; 22:1480-1490.
8. Garcia-Carbonero R, Supko JG, Maki RG, et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol 2005; 23:5484-5492.
9. Van Glabbekea M, Verweijb J, Judsonc I, et al. Progression-free rate as the principal endpoint for phase II trials in soft-tissue sarcomas. Eur J Cancer 2002; 38:543-549.
10. Demetri GD, Chawla SP, von Mehren M, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyo sarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 2009; 27:4188-4196.
11. LeCesne A, Demetri G, Jean L, et al. Impact ofyondelis in the natural history of patients with pretreated advanced soft tissue sarcoma: long term follow up results [abstract #31]. Abstract of the AACR-NCI-EORTC. International Conference on Molecular Targets and Cancer Therapeutics; Boston, Massachusetts, USA; 2003.
12. McCluggage WG. Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas? J Clin Pathol 2002; 55:460-469.
13. Reicha O, Regaue S. Hormonal therapy of endometrial stromal sarcoma. Curr Opin Oncol 2007; 19:347-352.
14. Major FJ, Blessing JA, Silverberg SG, et al. Prognostic factors in early-stage uterine sarcoma: a Gynecologic Oncology Group study. Cancer 1993; 71:1702-1709.
15. Amant F, Coosemans A, Renard V, et al. Clinical outcome of ET-743 (trabectedin;yondelis) in high-grade uterine sarcomas: report on five patients and a review of the literature. Int J Gynecol Cancer 2009; 19:245-248.
16. Grosso F, Sanfilippo R, Jones RL, et al. Role of trabectedin (T) in the management of advanced uterine leiomyosarcoma (U-LM) [abstract #10530]. J Clin Oncol 2009; 27 (Suppl):15s.
17. LookKY, Sandler A, Blessing JA, et al. Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) study. Gynecol Oncol 2004; 92:644-647.
18. Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 2002; 20:2824-2831.
19. Hensley ML, Blessing J, DeGeest K, et al. Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol Oncol 2008; 109: 323-328.
20. Hensley ML, Blessing J, Mannel R, Rose PG. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol 2008; 109:324-329.
21. Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. Clin Oncol 2007; 25:2755-2763.
22. Pautier P, Bui Nguyen B, Penel N, et al. Final results of a FNCLCC French Sarcoma Group multicenter randomized phase II study of gemcitabine (G) versus gemcitabine and docetaxel (G + D) in patients with metastatic or relapsed leiomyosarcoma (LMS) [abstract #10527]. J Clin Oncol 2009; 27 (Suppl):15s.
23. Grosso F, Jones RL, Demetri GD, et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 2007; 8:595-602.
24. Grosso F, Sanfilippo R, Virdis E, et al. Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. Ann Oncol 2009; 20:1439-1444.
25. Sanfilippo R, Grosso F, Virdis E et al. Rechallenge with trabectedin in patients with responding myxoid liposarcoma [abstract #10575]. J Clin Oncol 2009; 27 (Suppl):15s.
26. von Mehren M. Trabectedin: a targeted chemotherapy? Lancet Oncol 2007; 8:565-567.
27. Forni C, Minuzzo M, Virdis E, et al. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol Cancer Ther 2009; 8:449-457.
28. Grosso F, Jones R, Blay JY, et al., Connective Tissue Oncology Society. Trabectedin in soft tissue sarcoma carrying a chromosomal translocation: an exploratory analysis. In: 13th Annual Meeting; Seattle, Washington, USA; 2007 [abstract #900].
29. Takebayashi Y, Pourquier P, Zimonjic DB, et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-exci-sion repair. Nat Med 2001; 7:961-966.
30. Herrero AB, Martín-Castellanos C, Marco E, et al. Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res 2006; 66:8155-8162.
31. Tavecchio M, Simone M, Erba E, et al. Role of homologous recombination in trabectedin-induced DNA damage. Eur J Cancer 2008; 44:609-618.
32. Xing D, Scangas G, Nitta M. A role for BRCA1 in uterine leiomyosarcoma. Cancer Res 2009; 69:8231-8235.
33. Meco D, Colombo T, Ubezio P, et al. Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies. Cancer Chemother Pharmacol 2003; 52:131-138.
34. Takahashi N, Li WW, Banerjee D, et al. Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells. Clin Cancer Res 2001; 7:3251-3257.
35. Sessa C, Perotti A, Noberasco C, et al. Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer. Eur J Cancer 2009; 45:1153-1161.
36. Blay JY, von Mehren M, Samuels BL, et al. Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma. Clin Cancer Res 2008; 14:6656-6662.
37. von Mehren M, Schilder RJ, Cheng JD, et al. A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies. Ann Oncol 2008; 19:1802-1809.
38. Boudou L, Baconnier M, Blay JY, et al. Trabectedin for the management of soft-tissue sarcoma. Expert Rev Anticancer Ther 2009; 9:727-737.
39. Schoffski P, Dumez H, Wolter P, et al. Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma. Expert Opin Pharmacother 2008; 9:1609-1618.
40. Schoffski P, Cerbone L, Wolter P. Administration of 24-h intravenous infusions of trabectedin every 3 weeks in ambulatory patients with mesenchymal tumors via disposable elastomeric pumps [abstract #e13530]. J Clin Oncol 2009; 27 (Suppl).
41. Grosso F, Dileo P, Sanfilippo R, et al. Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. Eur J Cancer 2006; 42:1484-1490.
42. Donald S, Verschoyle RD, Greaves P, et al. Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat. Cancer Res 2003; 63:5902-5908.
43. van Waterschoot RA, Eman RM, Wagenaar E, et al. ABCC2, ABCC3, and ABCB1, but not CYP3A, protect against trabectedin-mediated hepatotoxicity. Clin Cancer Res 2009; 15:7616-7623.